ArticleJournal of medical biochemistry2025
Impact of PDCA cycle-driven nutritional support on serum biomarkers and quality of life in nasopharyngeal carcinoma patients undergoing radiotherapy.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to assess the effectiveness of nutritional support guided by the PDCA (Plan-Do-Check-Act) cycle management model in nasopharyngeal carcinoma (NPC) patients undergoing radiotherapy. Methods: A total of 100 NPC patients between December 2021 and October 2023 were randomly assigned to two groups: an observation group (OG, n = 50) and a control group (CG, n = 50). The CG received routine nutritional support, while the OG received nutritional support based on the PDCA cycle. Key outcomes included blood nutritional biomarkers, quality of life (QoL), incidence of adverse reactions (ARs), and clinical efficacy. Results: Post-treatment analysis showed that the OG had a significantly higher total effective rate (72%) compared to the CG (38%) (P< 0.05). The OG also showed higher albumin, prealbumin, and total protein levels and lower CRP levels after treatment. The OG significantly improved cognitive, role, social, physical, and emotional functioning (P< 0.05). The AR rate was considerably lower in the OG (20%) compared to the CG (36%) (P< 0.05). Conclusions: These results suggest that PDCA cycle-based nutritional support enhances clinical efficacy and QoL, reduces nutritional risks and adverse reactions and improves overall safety in NPC patients undergoing radiotherapy. Serum markers like serum iron, ferritin, prealbumin, and CRP effectively monitored the impact of nutritional interventions on patients' nutritional and inflammatory status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.